VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2012 by Institute of Vision, Brasil.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Institute of Vision, Brasil
ClinicalTrials.gov Identifier:
NCT01655589
First received: July 31, 2012
Last updated: NA
Last verified: July 2012
History: No changes posted

July 31, 2012
July 31, 2012
January 2008
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents
VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration

The main purpose of this study is to investigate the association between VEGF gene polymorphism and the response to intravitreal drugs in neovascular age-related macular degeneration. This is a retrospective review of patients treated between 2008 and 2012 at the Institute of Vision, in Belo Horizonte, Brazil.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Eye clinic in Belo Horizonte, Brazil

Macular Degeneration
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
74
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of neovascular age-related macular degeneration
  • Visual acuity better than 20/400
  • Loading dose with three intravitreal injections of anti-VEGF agents, administred one per month over three months
  • Follow-up period of at least six months

Exclusion Criteria:

  • Choroidal neovascularization secondary to any other cause than age-related macular degeneration
  • Eyes with polypoidal choroidal vasculopathy
  • Eyes previously submitted to posterior vitrectomy
  • Other diseases that could affect visual acuity
Both
50 Years and older
No
Brazil
 
NCT01655589
IV-01
Not Provided
Institute of Vision, Brasil
Institute of Vision, Brasil
Not Provided
Not Provided
Institute of Vision, Brasil
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP